Early Response to Antipsychotic Drug Therapy as a Clinical Marker of Subsequent Response in the Treatment of Schizophrenia

Bruce J. Kinon; Lei Chen; Haya Ascher-Svanum; Virginia L. Stauffer; Sara Kollack-Walker; Wei Zhou; Shitij Kapur; John M. Kane

doi:10.1038/npp.2009.164

Early Response to Antipsychotic Drug Therapy as a Clinical Marker of Subsequent Response in the Treatment of Schizophrenia

Bruce J. Kinon, Lei Chen, Haya Ascher-Svanum, Virginia L. Stauffer, Sara Kollack-Walker, Wei Zhou, Shitij Kapur, John M. Kane

Research output: Contribution to journal › Article › peer-review

168 Citations (Scopus)

Abstract

Our objective was to prospectively assess whether early (ie, 2 weeks) response to an antipsychotic predicts later (12-week) response and whether 'switching' early non-responders to another antipsychotic is a better strategy than 'staying'. This randomized, double-blind, flexible-dosed, 12-week study enrolled 628 patients diagnosed with schizophrenia or schizoaffective disorder. All initiated treatment with risperidone. Early response was defined as >= 20% improvement on the Positive and Negative Syndrome Scale (PANSS) total score following 2 weeks of treatment. Early responders (ERs) continued on risperidone, whereas early non-responders (ENRs) were randomized (1 : 1) to continue on risperidone 2-6 mg/day or switch to olanzapine 10-20 mg/day for 10 additional weeks. Compared with ENRs, risperidone ERs showed significantly greater reduction in PANSS total score (end point; p

Original language	English
Pages (from-to)	581 - 590
Number of pages	10
Journal	Neuropsychopharmacology
Volume	35
Issue number	2
DOIs	https://doi.org/10.1038/npp.2009.164
Publication status	Published - Jan 2010

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/npp.2009.164

Cite this

@article{4015db8f1b26463a90512534c13e450e,

title = "Early Response to Antipsychotic Drug Therapy as a Clinical Marker of Subsequent Response in the Treatment of Schizophrenia",

abstract = "Our objective was to prospectively assess whether early (ie, 2 weeks) response to an antipsychotic predicts later (12-week) response and whether 'switching' early non-responders to another antipsychotic is a better strategy than 'staying'. This randomized, double-blind, flexible-dosed, 12-week study enrolled 628 patients diagnosed with schizophrenia or schizoaffective disorder. All initiated treatment with risperidone. Early response was defined as >= 20% improvement on the Positive and Negative Syndrome Scale (PANSS) total score following 2 weeks of treatment. Early responders (ERs) continued on risperidone, whereas early non-responders (ENRs) were randomized (1 : 1) to continue on risperidone 2-6 mg/day or switch to olanzapine 10-20 mg/day for 10 additional weeks. Compared with ENRs, risperidone ERs showed significantly greater reduction in PANSS total score (end point; p",

author = "Kinon, {Bruce J.} and Lei Chen and Haya Ascher-Svanum and Stauffer, {Virginia L.} and Sara Kollack-Walker and Wei Zhou and Shitij Kapur and Kane, {John M.}",

year = "2010",

month = jan,

doi = "10.1038/npp.2009.164",

language = "English",

volume = "35",

pages = "581 -- 590",

journal = "Neuropsychopharmacology",

issn = "1740-634X",

publisher = "Springer Nature [academic journals on nature.com]",

number = "2",

}

TY - JOUR

T1 - Early Response to Antipsychotic Drug Therapy as a Clinical Marker of Subsequent Response in the Treatment of Schizophrenia

AU - Kinon, Bruce J.

AU - Chen, Lei

AU - Ascher-Svanum, Haya

AU - Stauffer, Virginia L.

AU - Kollack-Walker, Sara

AU - Zhou, Wei

AU - Kapur, Shitij

AU - Kane, John M.

PY - 2010/1

Y1 - 2010/1

N2 - Our objective was to prospectively assess whether early (ie, 2 weeks) response to an antipsychotic predicts later (12-week) response and whether 'switching' early non-responders to another antipsychotic is a better strategy than 'staying'. This randomized, double-blind, flexible-dosed, 12-week study enrolled 628 patients diagnosed with schizophrenia or schizoaffective disorder. All initiated treatment with risperidone. Early response was defined as >= 20% improvement on the Positive and Negative Syndrome Scale (PANSS) total score following 2 weeks of treatment. Early responders (ERs) continued on risperidone, whereas early non-responders (ENRs) were randomized (1 : 1) to continue on risperidone 2-6 mg/day or switch to olanzapine 10-20 mg/day for 10 additional weeks. Compared with ENRs, risperidone ERs showed significantly greater reduction in PANSS total score (end point; p

AB - Our objective was to prospectively assess whether early (ie, 2 weeks) response to an antipsychotic predicts later (12-week) response and whether 'switching' early non-responders to another antipsychotic is a better strategy than 'staying'. This randomized, double-blind, flexible-dosed, 12-week study enrolled 628 patients diagnosed with schizophrenia or schizoaffective disorder. All initiated treatment with risperidone. Early response was defined as >= 20% improvement on the Positive and Negative Syndrome Scale (PANSS) total score following 2 weeks of treatment. Early responders (ERs) continued on risperidone, whereas early non-responders (ENRs) were randomized (1 : 1) to continue on risperidone 2-6 mg/day or switch to olanzapine 10-20 mg/day for 10 additional weeks. Compared with ENRs, risperidone ERs showed significantly greater reduction in PANSS total score (end point; p

U2 - 10.1038/npp.2009.164

DO - 10.1038/npp.2009.164

M3 - Article

SN - 1740-634X

VL - 35

SP - 581

EP - 590

JO - Neuropsychopharmacology

JF - Neuropsychopharmacology

IS - 2

ER -

Early Response to Antipsychotic Drug Therapy as a Clinical Marker of Subsequent Response in the Treatment of Schizophrenia

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this